Immune Engineering -
from Molecules to Therapeutic Approaches
December 1, 2023
2nd Joint Meeting of GBM & BioPharma Cluster South Germany
Dear colleagues and friends,
Following our successful joint event on RNA Therapeutics last year, we will continue our collaboration and would like to invite you to the 2nd joint event of the BioPharma Cluster South Germany and the German Society for Biochemistry and Molecular Biology (GBM).
This year, we will focus on translational research in immune engineering, covering basic research, drug development and manufacturing, and clinical application. The patients' perspective will also be addressed in the panel discussion. The target audience is researchers, developers and engineers from industry and academia, young scientists, physicians, and anyone who would like to have a look at the big picture of what we do for patients with our contributions in research, engineering, manufacturing, analytical testing and clinical application.
At the end of the event, we offer all participants the opportunity for exchange and networking.
We would be pleased to welcome you on December 1st at the “Stadthaus” in Ulm at the Münster Platz hosting Ulm´s Christmas Market at that time and look forward to an inspiring meeting and networking event!
(Senior Advisor Biopharmaceuticals, Boehringer Ingelheim; Chairman of the BioPharma Cluster South Germany)
13:00 - 14:30
Matthias Feige /Technical University Munich
Targeting and engineering immune cell communication for novel therapies
Dirk Busch /Technical University Munich
Advanced T cell receptor engineering for repertoire analysis and cell therapies
Andrea Schmidts /Technical University Munich
Engineering resilient chimeric antigen receptor (CAR)-T cell therapies
14:30 - 14:45 Coffee Break
14:45 - 15:45
Process Development and Supply of Biopharmaceuticals:
Moderation: Uwe Bücheler/Boehringer Ingelheim
Ann-Cathrin Leroux /Sartorius
Cell Line Development
Christiane Bardroff /Rentschler Biopharma
Drug Substance and Process Development
Jörg Zimmermann /Vetter
Drug product and Process Development
Stefan Ottmar Fügenschuh /Teva Biotech
Large Scale Manufacturing of Biopharmaceuticals
15:45 - 16:30
Stephan Stilgenbauer /University Hospital Ulm
From Biology to Targeted Therapy in Cancer
16:30 - 17:00 Coffee Break
17:00 - 18:00
Translation zu Ende gedacht - Was brauchen und nützt Patienten?
Uwe Bücheler (BioPharma Cluster)
Stephan Stilgenbauer (Oncology)
Klaus-Michael Debatin (Rare Diseases)
Tanja Vetter, Norman Roßberg (alle Patientenbeirat Comprehensive Cancer Center Ulm)
(Moderation: Dorothee Ambrosius (Senior Advisor Biopharma /Laupheim)
18:00 - 20:00
Networking with fingerfood
The registration & participation is free!
Registration deadline: November 24
Participation in the conference is free of charge but the number of places is limited.
Therefore, we kindly ask you to cancel your participation in time if you find that you will not be able to attend, in order to allow other interested persons to participate.
Organization & Contact
Gesellschaft für Biochemie
und Molekularbiologie e.V.
Mörfelder Landstr. 125
60598 Frankfurt am Main
Phone: +49 69 660567-0